Brentuximab vedotin, an anti-CD30 antibody, anti-tubulin drug conjugate was used in a patient with relapsed CD30-positive ALCL with systemic and CNS disease after previous MTX failure. This evidence concerns the gene TNFRSF8 and anaplastic large cell lymphoma.